Assessment of dual-time-point 18F-FDG-PET imaging for pulmonary lesions

Laffon, Éric; Clermont, Henri de; Bégueret, Hugues; Vernejoux, J.-M.; Thumerel, Matthieu; Marthan, Roger; Ducassou, D.

doi:10.1097/mnm.0b013e32832bdcac

Cited by 47 publications

(23 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Recently, similar to the present study, Laffon et al [29] conducted a study to assess suitability of dual-time-point 18 F FDG PET imaging for differentiating between malignant and benign pulmonary lesions. In their study, they recommended that dual-time-point 18 F FDG PET imaging is not indicated to differentiate between malignant and benign pulmonary lesions.…”

Section: Discussionmentioning

confidence: 52%

Limited diagnostic and predictive values of dual-time-point 18F FDG PET/CT for differentiation of incidentally detected thyroid nodules

Kim

Jeon

et al. 2011

Ann Nucl Med

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 52%

Limited diagnostic and predictive values of dual-time-point 18F FDG PET/CT for differentiation of incidentally detected thyroid nodules

Kim

Jeon

et al. 2011

Ann Nucl Med

View full text Add to dashboard Cite

show abstract

“…For example, differentiation between malignant and inflammatory lesions was not consistently successful using DTPI because some studies have shown nonspecificity in lung and mediastinal lesions and lung nodules with low FDG uptake. 42,66,68,69,[87][88][89] In addition, acute infectious and noninfectious inflammatory lesions, specifically granulomatous lesions, show a pattern similar to the malignant lesions 90,91 and therefore DTPI is not considered to be superior to STPI in the areas with high prevalence of sarcoidosis and in tuberculosis (TB)-endemic areas. 42,66,68,69,88,89,92 However, DTPI is still a useful option for differentiation of inactive granulomatous or chronic inflammatory lesions from malignancy because of difference in the biological behavior of the cells involved in the chronic versus acute inflammation.…”

Section: Challenges Summary and Future Directionsmentioning

confidence: 96%

“…6-9) with some limitations reported in the literature, including false-positive and false-negative results. 4,5,42 However, over delayed times of 2 or 3 hours, the lymph nodes become clearer and easier to detect compared with 1-hour imaging.…”

Section: Applications Of Dual-time-point Imaging In Malignant Diseasementioning

confidence: 98%

Dual-time-point Imaging and Delayed-time-point Fluorodeoxyglucose-PET/Computed Tomography Imaging in Various Clinical Settings

et al. 2016

View full text Add to dashboard Cite

“…35 Ten publications 28,29,31,33,34,[36][37][38][39][40] fulfilled all of the inclusion criteria, with a total of 816 patients and 890 pulmonary nodules. Multiple different thresholds were used to define a pulmonary nodule as malignant between the initial and later images.…”

Section: Lung Cancermentioning

confidence: 99%

Use of Dual-Point Fluorodeoxyglucose Imaging to Enhance Sensitivity and Specificity

Schillaci

2012

Seminars in Nuclear Medicine

View full text Add to dashboard Cite

Positron emission tomography (PET) and positron emission tomography/computed tomography imaging with fluorodeoxyglucose (FDG) are widely used as a powerful evaluation modality in oncological nuclear medicine not only for detecting tumors but also for staging and for therapy monitoring. Nevertheless, there are numerous causes of FDG uptake in benign processes seen on PET images. In fact, the degree of FDG uptake is related to the cellular metabolic rate and the number of glucose transporters. FDG accumulation in tumors is due, in part, to an increased number of glucose transporters in malignant cells. However, FDG is not specific for neoplasms: a similar situation exists in inflammation; activated inflammatory cells demonstrate increased expression of glucose transporters. Therefore, there is growing interest in improving the specificity of FDG-PET in patients with cancer. Preliminary studies showed that in several neoplasms, the uptake of FDG continues to increase for hours after radiopharmaceutical injection, and this difference in the time course of FDG uptake could be useful to improve the accuracy of PET to distinguish benign lesions from malignant ones. Also in experimental cultures, dual-point acquisition (early at 40-60 minutes postinjection and delayed at 90-270 minutes) demonstrated that it is able to differentiate inflammatory from neoplastic tissue. In general, inflammatory tissue is expected to reduce FDG uptake as the time goes by, whereas the uptake in the neoplastic lesions is supposed to be increasing. There is evidence in the recent literature of the clinical usefulness of dual-time-point FDG-PET imaging in a wide variety of malignancies, including those of head and neck, lung, breast, gallbladder, cervix, liver, and in brain tumors. A lesion is likely to be malignant if the standard uptake value increases over time, whereas it is likely to be benign if the standard uptake value is stable or decreases. It is worth noting that in many of these studies, dual-time-point PET improved not only the specificity but also the sensitivity in assessing breast, pulmonary, liver, and other tumors because of increased lesion-to-background ratio, as a consequence of FDG washout from the surrounding normal tissues and increasing neoplastic uptake. Semin Nucl Med 42:267-280

show abstract

Assessment of dual-time-point 18F-FDG-PET imaging for pulmonary lesions

Cited by 47 publications

References 15 publications

Limited diagnostic and predictive values of dual-time-point 18F FDG PET/CT for differentiation of incidentally detected thyroid nodules

Limited diagnostic and predictive values of dual-time-point 18F FDG PET/CT for differentiation of incidentally detected thyroid nodules

Dual-time-point Imaging and Delayed-time-point Fluorodeoxyglucose-PET/Computed Tomography Imaging in Various Clinical Settings

Use of Dual-Point Fluorodeoxyglucose Imaging to Enhance Sensitivity and Specificity

Contact Info

Product

Resources

About